Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Net Cash Flow (2022 - 2026)

Sagimet Biosciences' Net Cash Flow history spans 5 years, with the latest figure at $1.6 million for Q1 2026.

  • Quarterly Net Cash Flow rose 114.43% to $1.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$28.1 million through Mar 2026, up 74.93% year-over-year, with the annual reading at -$40.8 million for FY2025, 5922.97% down from the prior year.
  • Net Cash Flow came in at $1.6 million for Q1 2026, down from $2.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $101.6 million in Q1 2024 to a low of -$80.8 million in Q2 2024.
  • The 5-year median for Net Cash Flow is -$1.6 million (2022), against an average of $2.0 million.
  • Year-over-year, Net Cash Flow soared 205766.67% in 2023 and then tumbled 1409.85% in 2024.
  • Sagimet Biosciences' Net Cash Flow stood at -$2.1 million in 2022, then crashed by 1166.15% to -$26.7 million in 2023, then skyrocketed by 95.6% to -$1.2 million in 2024, then skyrocketed by 315.08% to $2.5 million in 2025, then plummeted by 36.44% to $1.6 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Net Cash Flow are $1.6 million (Q1 2026), $2.5 million (Q4 2025), and -$9.8 million (Q3 2025).